NCT03062579View on ClinicalTrials.gov

A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 1, 2017

Primary Completion Date

February 15, 2018

Study Completion Date

May 15, 2018

Conditions
Neuromyelitis Optica Spectrum DisordersNeuromyelitis OpticaDevic's Disease
Interventions
DRUG

Tocilizumab

Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.

Trial Locations (1)

300052

Tianjin Medical University General Hospital, Tianjin

All Listed Sponsors
lead

Fu-Dong Shi

OTHER

NCT03062579 - A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD | Biotech Hunter | Biotech Hunter